Madrigal Pharmaceuticals, Inc. (MDGL) stock
Close on Nov 18, 2026Market cap $9.20BP/E –Yield –
Earnings
Madrigal Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Madrigal Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 18, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 3, 2026before the open | $431.30M | +50.1% | $1.83 | Release |
| Q2 FY2026ended Jun 30, 2026 | Jul 30, 2026before the open | $364.30M | +71.2% | $1.99 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026before the open | $311.30M | +126.7% | -$3.25 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 19, 2026before the open | $321.10M | +210.8% | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 4, 2025before the open | $287.30M | +361.9% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $212.80M | +1357.5% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 1, 2025before the open | $137.30M | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025before the open | $103.30M | – | -$2.71 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024before the open | $62.20M | – | -$4.92 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 7, 2024before the open | $14.60M | – | -$7.10 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | – | – | -$7.38 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024before the open | – | – | -$5.68 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023before the open | – | – | -$5.34 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | – | – | -$4.69 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023before the open | – | – | -$4.23 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023before the open | – | – | -$4.98 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022before the open | – | – | -$4.75 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | – | – | -$4.14 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 9, 2022before the open | – | – | -$3.36 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022before the open | – | – | -$3.78 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021before the open | – | – | -$3.79 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Madrigal Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Madrigal Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Madrigal Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate UpdatesResults
- Update
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate UpdatesResults
- Update
- Results
- Results
- Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate UpdatesResults
- Results
See a number that looks wrong?